(Total Views: 678)
Posted On: 09/20/2022 12:59:48 AM
Post# of 153984
So this is what the website says so CC should cover almost all our areas
We believe in the future of precision medicine
CytoDyn believes in the future of precision medicine... more specificity, less side effects. Our target, the CCR5 receptor, has been implicated in multiple disease processes from HIV, GvHD, NASH, stroke recovery, multiple sclerosis, COVID-19, NAFLD/NASH, to metastatic cancer. Leronlimab, our CCR5 antagonist, is a once-a-week, subcutaneous injection. One molecule with multiple opportunities.
We believe in the future of precision medicine
CytoDyn believes in the future of precision medicine... more specificity, less side effects. Our target, the CCR5 receptor, has been implicated in multiple disease processes from HIV, GvHD, NASH, stroke recovery, multiple sclerosis, COVID-19, NAFLD/NASH, to metastatic cancer. Leronlimab, our CCR5 antagonist, is a once-a-week, subcutaneous injection. One molecule with multiple opportunities.
(7)
(0)
